Search in:

Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 1

Submit an article Journal homepage

165

Views

CrossRef citations to date

Altmetric

Review

Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy

Jose Maria Pego-Reigosa Hospital do Meixoeiro (Complexo Hospitalario Universitario de Vigo), Rheumatology Section, Alto do Meixoeiro s/n, 36200 Vigo (Pontevedra), Spain +1 34 98 622 9912; +1 34 98 681 1169; [email protected]

, MD PhD &

David A Isenberg University College of London, Centre for Rheumatology Research, Division of Medicine, Room 331, 3rd Floor, The Windeyer Building, 46 Cleveland Street, London, W1T 4JF, UK

, MD FRCP

Pages 31-41 | Published online: 20 Dec 2007

Cite this article
https://doi.org/10.1517/13543784.17.1.31

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7
PubMed Web of Science ®Google Scholar
Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725
PubMed Web of Science ®Google Scholar
Gladmann DD, Urowitz MB. Prognosis, mortality and morbidity in systemic lupus erythematosus. In: Dubois Lupus Erythematosus. Wallace D, Hahn BH, (Eds), 6th Edition, Philadelphia: Lippincott, Williams, Wilkins; 2001. p. 54-6
Google Scholar
Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996;10:77-84
PubMed Web of Science ®Google Scholar
Chan TM, Li FK, Tang CSO, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000;343:1156-62
PubMed Web of Science ®Google Scholar
Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis, Nephrology 2005;10:504-10
PubMed Web of Science ®Google Scholar
Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis, Ellen M. N Engl J Med 2005;353:2219-28
PubMed Web of Science ®Google Scholar
Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80
PubMed Web of Science ®Google Scholar
Alba P, Karim MY, Hunt BJ, et al. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2003;12:633-5
PubMed Web of Science ®Google Scholar
Vasoo S, Thumboo J, Fong KY, et al. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 2003;12:630-2
PubMed Web of Science ®Google Scholar
Karim MY, Alba P, Cuadrado MJ, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002;41:876-82
PubMed Web of Science ®Google Scholar
Pisoni CN, Obermoser G, Cuadrado MJ, et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005;23:393-6
PubMed Web of Science ®Google Scholar
Kreuter A, Tomi NS, Weiner SM, et al. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol 2007;156:1321-7
PubMed Web of Science ®Google Scholar
Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999;169:107-21
PubMed Web of Science ®Google Scholar
Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000;165:5970-9
PubMed Web of Science ®Google Scholar
Arce E, Jackson DG, Gill MA, et al. Increased frequency of pre-germinal center B cells and plasma cell precursors in the Blood of children with systemic lupus erythematosus. J Immunol 2001;167:2361-9
PubMed Web of Science ®Google Scholar
Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1332-42
PubMed Web of Science ®Google Scholar
Valentine MA, Meier KE, Rossie S, et al. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. J Biol Chem 1989;264:11282-7
PubMed Web of Science ®Google Scholar
Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B-cell-associated antigens on leukemias and lymphomas: a model of human B-cell differentiation. Blood 1984;63:1424-33
PubMed Web of Science ®Google Scholar
Tedder TF, Boyd AW, Freedman AS, et al. The B-cell surface molecule B1 is functionally linked with B-cell activation and differentiation. J Immunol 1985;135:973-9
PubMed Web of Science ®Google Scholar
Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45
PubMed Web of Science ®Google Scholar
Alas S, Ng CP, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signalling pathway, resulting in apoptosis in cisplatin non-Hodgkins lymphoma. Clin Cancer Res 2002;8:836-45
PubMed Web of Science ®Google Scholar
Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7
PubMed Web of Science ®Google Scholar
Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58
PubMedGoogle Scholar
Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005;44:1542-5
PubMed Web of Science ®Google Scholar
Ng KP, Leandro MJ, Edwards JC, et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006;65:942-5
PubMed Web of Science ®Google Scholar
Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007;66:1259-62
PubMed Web of Science ®Google Scholar
Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9
PubMed Web of Science ®Google Scholar
Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-9
PubMed Web of Science ®Google Scholar
Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580-90
PubMed Web of Science ®Google Scholar
Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52:501-13
PubMed Web of Science ®Google Scholar
Gunnarsson I, Sundelin B, Jonsdottir T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007;56:1263-72
PubMed Web of Science ®Google Scholar
Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997;15:481-504
PubMed Web of Science ®Google Scholar
Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74
PubMed Web of Science ®Google Scholar
Jacobi AM, Goldenberg DM, Hiepe FT, et al. Differential effects of epratuzumab on peripheral Blood B cells of SLE patients versus normal controls. Ann Rheum Dis 2007; [Epub ahead of print]
PubMedGoogle Scholar
Thompson JS, Bixler SA, Qian F, et al. BAAF-R, a novel TNF receptor that specifically interacts with BAAF. Science 2001;293:2108-11
PubMed Web of Science ®Google Scholar
Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285:260-3
PubMed Web of Science ®Google Scholar
Huard B, Schneider P, Mauri D, et al. T cell costimulation by the TNF ligand BAAF. J Immunol 2001;167:6225-31
PubMed Web of Science ®Google Scholar
Roschke V, Sosnovtseva S, Ward CD, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002;169:4314-21
PubMed Web of Science ®Google Scholar
Stohl W, Metyas S, Tan SM, et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004;63:1096-103
PubMed Web of Science ®Google Scholar
Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48:3475-86
PubMed Web of Science ®Google Scholar
Ju S, Zhang D, Wang Y, et al. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem 2006;39:1131-7
PubMed Web of Science ®Google Scholar
Furie, Stohl W, Ginzler E, et al. Safety, pharmacokinetic and pharmacodynamic results of a Phase I single and double dose escalation study of lymphostat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum 2003;48:S377
Web of Science ®Google Scholar
Wallace DJ, Lisse J, Stohl W, et al. Belimumab (BMAB), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), shows bioactivity and reduces systemic lupus erythematosus disease activity. Ann Rheum Dis 2006;65:62
Google Scholar
Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999;8:685-91
PubMed Web of Science ®Google Scholar
Jones DS, Hachmann JP, Osgood SA, et al. Conjugates of double-stranded oligonucleotides with poly(ethylene glycol) and keyhole limpet hemocyanin: a model for treating systemic lupus erythematosus. Bioconjug Chem 1994;5:390-9
PubMed Web of Science ®Google Scholar
Hartley SB, Cooke MP, Fulcher DA, et al. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell 1993;72:325-35
PubMed Web of Science ®Google Scholar
Norvell A, Mandik L, Monroe JG. Engagement of the antigen-receptor on immature murine B lymphocytes results in death by apoptosis. J Immunol 1995;154:4404-13
PubMed Web of Science ®Google Scholar
Weisman MH, Bluestein HG, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997;24:314-18
PubMed Web of Science ®Google Scholar
Alarcon-Segovia D, Tumlin JA, Furie RA, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-54
PubMed Web of Science ®Google Scholar
Strand V, Aranow C, Cardiel MH, et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003;12:677-86
PubMed Web of Science ®Google Scholar
Linnik MD, Hu JZ, Heilbrunn KR, et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52:1129-37
PubMed Web of Science ®Google Scholar
Janeway CA Jr, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994;76:275-85
PubMed Web of Science ®Google Scholar
Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a Phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71
PubMed Web of Science ®Google Scholar
Finck BK, Linsley Ps, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7
PubMed Web of Science ®Google Scholar
Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nehritis with CTLA4Ig and cyclophosphamide. J Immunol 2001;166:2913-6
PubMed Web of Science ®Google Scholar
Cunnane G, Chan OT, Cassafer G, et al. Prevention of renal damage in murine lupus nephritis by CTLA4Ig and cyclophosphamide. Arthritis Rheum 2004;50:1539-48
PubMed Web of Science ®Google Scholar
Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-35
PubMed Web of Science ®Google Scholar
Durie FH, Foy TM, Masters SR, et al. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994;15:406-11
PubMedGoogle Scholar
Davis JC Jr, Totoritis MC, Rosenberg J, et al. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001;8:95-101
Google Scholar
Kalunian KC, Davis JC Jr, Merrill JT, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:3251-8
PubMed Web of Science ®Google Scholar
Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48:719-27
PubMed Web of Science ®Google Scholar
Sthoeger ZM, Dayan M, Tcherniack A, et al. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin Exp Immunol 2003;131:385-92
PubMed Web of Science ®Google Scholar
Sharabi A, Azulai H, Sthoeger ZM, Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology 2007;121:248-57
PubMed Web of Science ®Google Scholar
Sthoeger ZM, Dayan M, Tcherniack A, et al. Modulation of autoreactive responses of peripheral Blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin Exp Immunol 2003;131:385-92
PubMed Web of Science ®Google Scholar
Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune ‘lupus’ nephritis. Nature 1988;331:356-8
PubMed Web of Science ®Google Scholar
de Rycke L, Baeten D, Kruithof E, et al. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005;52:2192-201
PubMed Web of Science ®Google Scholar
Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007;86:242-51
PubMed Web of Science ®Google Scholar
Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50:3161-9
PubMed Web of Science ®Google Scholar
Aringer M, Houssiau FA, Graninger WB, et al. Open-label infliximab for systemic lupus erythematosus: long-term follow-up of 11 patients. Arthritis Rheum 2006;54:S260-1
Google Scholar
Yu CL, Sun KH, Tsai CY, et al. Anti-dsDNA antibody up-regulates interleukin 6, but not cyclo-oxygenase, gene expression in glomerular mesangial cells: a marker of immune-mediated renal damage? Inflamm Res 2001;50:12-8
PubMed Web of Science ®Google Scholar
Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994;94:585-91
PubMed Web of Science ®Google Scholar
Liang B, Gardner DB, Griswold DE, et al. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006;119:296-305
PubMed Web of Science ®Google Scholar
Ripley BJ, Goncalves B, Isenberg DA, et al. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis 2005;64:849-53
PubMed Web of Science ®Google Scholar
Shirota Y, Yarboro C, Sims G, et al. The impact of in vitro anti-receptor blockade on circulating T- and B-cell subsets in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52:S697
PubMed Web of Science ®Google Scholar
Houssiau FA, Lefebvre C, van den Berghe M, et al. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995;4:393-5
PubMed Web of Science ®Google Scholar
Park YB, Lee SK, Kim DS, et al. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998;16:283-8
PubMed Web of Science ®Google Scholar
Llorente L, Richaud-Patin Y, Garcia-Padilla C, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000;43:1790-800
PubMed Web of Science ®Google Scholar
Santiago-Raber ML, Baccala R, Haraldsson KM, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003;197:777-88
PubMed Web of Science ®Google Scholar
Hron JD, Peng SL. Type I IFN protects against murine lupus. J Immunol 2004;173:2134-42
PubMed Web of Science ®Google Scholar
Rönnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthrits Rheum 2006;54:408-20
PubMed Web of Science ®Google Scholar
Bao L, Osawe I, Puri T, et al. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol 2005;35:2496-506
PubMed Web of Science ®Google Scholar
Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004;13:168-76
PubMed Web of Science ®Google Scholar
Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006;295:527-35
PubMed Web of Science ®Google Scholar
Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003;48:166-73
PubMed Web of Science ®Google Scholar
Gladstone DE, Prestrud AA, Pradhan A, et al. High-dose cyclophosphamide for severe systemic lupus erythematosus. Lupus 2002;11:405-10
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date